KURA has been granted a new patent
Feb 05, 2025, 11:36 PM
-14.96%
What does KURA do
Kura Oncology, headquartered in San Diego, focuses on developing precision medicines for cancer treatment, including small molecule candidates Ziftomenib, Tipifarnib, and KO-2806. The company went public in November 2015 and employs 142 staff.
KURA filed a patent for "crystalline forms of a menin inhibitor" on Mon, July 17, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.